MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma

MYC and MYCN are the most commonly amplified oncogenes in medulloblastoma. Their overall association with a poor prognosis has supported their adoption as high-risk disease biomarkers in trials. However, emerging evidence suggests that certain patients with MYN/MYCN focally-amplified tumours can ach...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwalbe, Edward, Lindsey, Janet, Hill, Rebecca, Crosier, Stephen, Ryan, Sarra, Williamson, Daniel, Kool, Marcel, Milde, Till, Pfister, Stefan, Bailey, Simon, Clifford, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Medulloblastoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165081/
http://dx.doi.org/10.1093/neuonc/noac079.410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165081/
http://dx.doi.org/10.1093/neuonc/noac079.410

Ejemplares similares